Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase – Should You Buy?

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw strong trading volume on Thursday . 105,365 shares traded hands during trading, an increase of 247% from the previous session’s volume of 30,375 shares.The stock last traded at $7.78 and had previously closed at $7.21.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a report on Wednesday.

Aligos Therapeutics Stock Performance

The stock’s fifty day moving average price is $10.59 and its two-hundred day moving average price is $13.53. The company has a market cap of $656.12 million, a P/E ratio of -6.56 and a beta of 2.16.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. The business had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same period in the previous year, the company earned ($10.75) EPS. On average, equities research analysts forecast that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Armistice Capital LLC increased its position in Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after acquiring an additional 363,000 shares during the period. Acadian Asset Management LLC grew its holdings in Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after purchasing an additional 171,490 shares during the period. Finally, Opaleye Management Inc. grew its holdings in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares during the period. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).